SIU 2014 High PIRADS Final
Transcription
SIU 2014 High PIRADS Final
Correla'on of High PIRADS Score on Three-‐Tesla Magne'c Resonance with in-‐Gantry Magne'c Resonance Guided Biopsy Insert your logos R Jyo', N Hamesh Jina, H Haxhimolla Calvary Hospital, Bruce, ACT, Australia BACKGROUND Prostate cancer detection is a difficult process despite the various modalities available. The current standard of practice is based on stratifying risk using Prostate Specific Antigen (PSA), digital rectal examination (DRE) and performing a transrectal ultrasound (TRUS) or transperineal (TP) guided biopsy. There are limitations with this tool which include a 21% false negative rate using the standard 12 core approach(1), a 42% false negative rate with saturation sampling and a 30-45% risk of cancer up/downstaging (2) Recent advances in three-tesla multiparametric magnetic resonance imaging (MP-MRI) technology has revolutionised prostate cancer detection. In particular, the availability of ingantry MRI guided biopsies (MRGB) have added another diagnostic tool to help facilitate this and superior over TRUS biopsies (3). The literature has shown that prostate cancer detection rates range from 37-59% with 93% of clinically significant disease being detected with this modality.(4-6) RESULTS IMAGES MATERIALS & METHODS We retrospectively present the results from a single surgeon working in a tertiary hospital who performed MRI guided biopsies over a 15 month period from December 2012. Patients recruited in the study were high risk which qualified as having an elevated PSA (>2.5) on more than one reading and/or a palpable nodule on rectal examination or ultrasound, or a previous negative TRUS biopsy The MRI was interpreted by a single experienced genitourinary MRI radiologist and the biopsies were interpreted by a single pathologist. A single report was generated which was standardised and scored as per a modified PIRADS criteria. If the resoluDo (400 or 600 dp not higher tha There were 121 patients who had PIRADS 4+ lesions comprising of which were suspicious for a cancer with 75 patients having a PIRADS score 4 and 46 patients having a PIRADS score 5. There were 38 patients in the PIRADS 4 group (51%) who had a previous negative TRUS and 18 in the PIRADSS 5 group (39%). *To resize an i Shia key down resize the ima There were 77 patients (mean age of 63) with high PIRADS score (4 and 5) that underwent in-gantry MRGB. Out of the total 77 high PIRADS patients, 54 were PIRADS score 4 (70%) and 23 PIRADS score 5 (30%). There were 22 positive biopsies for adenocarcinoma of prostate with Gleason’s score of 3+3=6 or higher. Out of the 54 PIRADS score 4 lesions, 13 were positive (24%) and out of 23 PIRADS 5 lesions, 9 were positive (39%). The remaining 55 biopsies were negative for prostate cancer.. (Delete this bo This is only a r REFERENCES 1. Noguchi M et al. RelaDonship between systemaDc biopsies and histological features of 222 radical prostatectomy specimens: lack of predicDon of tumour significance for men with nonpalpable prostate cancer. J Urol 2001; 166: 104-‐109 2. King CR et al. Extended prostate biopsy scheme improves reliability of Gleason grading implicaDonsfor radiotherpy paDents. Int J Radiat Oncol 2004; 59: 386-‐391 3. Hoeks et al. Three-‐Tesla MagneDc Resonance–Guided Prostate Biopsy in Men With Increased Prostate-‐Specific AnDgen and Repeated, NegaDve, Random, SystemaDc, Transrectal Ultrasound Biopsies: DetecDon of Clinically Significant Prostate Cancers. Euro Uro 2012; 62: 902-‐909 4. Hambrock T et al. MagneDc resonance imaging guided prostate biopsy in men with repeat negaDve biopsies and increased pros_e specific anDgen. J Urol 2012; 183: 520-‐27 5.Roethke M et al. MRI-‐guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 paDents aaer previous negaDve TRUS biopsy. World J Urol 6. Franiel T et al. Areas suspicious for prostate cancer: MR-‐guided biopsy in paDents with at least one transrectal US-‐guided biopsy with a negaDve finding—mulDparametric MR imaging for detecDon and biopsy planning. Radiology 2011;259:162–72. All the biopsies were performed utilizing DynaTrim (Invivo Inc) prostate biopsy system on a three-tesla MRI scanner (Philips Ingenia 3.0T). Two to three samples were obtained from each lesion. CONCLUSIONS MRI is now widely used as a diagnostic tool for the detection of prostate cancer in patients who have had negative TRUS biopsies, a persistently elevated PSA and/or a prostate nodule clinically or on ultrasound. We present our series of MRGB in patients with a high PIRADS score for prostate cancer. Our results do support a role for MRGB and our positive biopsy rates of 24% with PIRADS four lesions and 39% with PIRADS five lesions which is lower than other studies (52-59%), however not all our patients with high PIRADS score underwent MRGB. Brisbane series showed that MRI reduces the need for biopsies by 51% and increased the detection of intermediate/high grade cancer by 17.7%. None of our patients have had disease which has been missed and this is supported with a negative predictive value of 96.9% with MRGB While this diagnostic paradigm is in its infancy stages, MRGB represents an excellent modality for prostate cancer diagnosis and should be considered in the management of this condition. Image checkin image (72 dpi right click on i pop-‐up windo scale. The ima height scale is If the scale of replace it with image if possib manually stret We recruited 191 patients who met the criteria. The mean age of the patients was 63 with a majority Caucasian background. The average size of the gland biopsied on MRI was 73cc (17-263cc range) with a median PSA of 6.37ng/ml (0.91-15.9ng/ml range). OBJECTIVES We review MRGB performed on high PIRADS score (Prostate Imaging Reporting And Data System) lesions. Our aim is to correlate the high PIRADS score with the histology from the in-gantry biopsies. Note: Skip the were created i Excel. Figures 1-‐4: Images from paDents with a IRADS 5 lesion which had posiDve biopsies ACKNOWLEDGEMENTS Dr Sanjiv Jain, Pathologist, ACT Health, Australia CONTACT INFORMATION: Dr N Hamesh Jina. Email: [email protected] Tip How to chang the poster 'tl Right click on When the pop color under “F effects select F (Delete this b Ti Copy and past stretched to fi of the chart, w chart in Excel, (Delete this b